Summary: Director Vicki L. Sato of Vir Biotechnology, Inc. (NASDAQ:VIR) sold 22,000 shares of the company's common stock on April 1, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The sale was completed under a pre-arranged Rule 10b5-1 trading plan and generated total proceeds of $199,616 at a weighted average price of $9.0735.
Per the filing, the prices realized in the transaction ranged from $8.87 to $9.20. The 10b5-1 plan governing these trades was established on March 27, 2025. After the sale, Sato retains direct ownership of 1,100,391 shares of Vir Biotechnology common stock.
At the time of the filing, Vir's shares were trading at $9.22 and the company carried a market capitalization of $1.49 billion. The insider sale occurs against a backdrop of notable recent share performance - the stock has delivered a 59% return over the prior six months.
Capital markets activity and analyst coverage
Vir recently completed a public offering of common stock that raised approximately $172.5 million in gross proceeds. That offering sold 20,294,117 shares at a public offering price of $8.50 per share. Earlier disclosures also referenced a $150 million stock offering priced at $8.50 per share, which included an option for underwriters to buy additional shares and thereby potentially increase proceeds.
Analyst sentiment cited in the filing shows an optimistic stance from several firms. H.C. Wainwright raised its price target on Vir to $20, and Leerink Partners also lifted its price target to $20, with both firms pointing to Vir's strategic collaboration with Astellas Pharma on a treatment for metastatic prostate cancer and to the company's recent capital raise. Across the analyst community referenced, price targets range from $17 to $30.
Valuation commentary and resources
According to InvestingPro analysis mentioned in the filing, Vir's stock appears slightly undervalued at current levels. For investors seeking more detailed valuation and financial analysis, a Pro Research Report is available for Vir and for more than 1,400 other U.S. equities through the InvestingPro service.
Key takeaways
- Director Vicki L. Sato sold 22,000 shares on April 1, 2026 at a weighted average price of $9.0735, producing $199,616 in proceeds.
- The sales were made under a Rule 10b5-1 plan established on March 27, 2025; Sato now directly owns 1,100,391 shares.
- Vir has recently raised capital via a public offering that brought in about $172.5 million by selling 20,294,117 shares at $8.50 apiece, and analysts have raised price targets to as high as $30.
Risks and uncertainties
- Share dilution risk tied to recent and previously announced stock offerings - the company sold millions of shares as part of public offerings at $8.50 per share, which could affect existing shareholders.
- Company prospects and valuation remain subject to analyst assumptions and future developments - price targets cited range from $17 to $30, indicating differing expectations among analysts.
- Dependence on strategic collaborations - analyst comments referenced Vir's partnership with Astellas Pharma on a metastatic prostate cancer program as a driver of sentiment, a relationship whose progress could influence market views.
This report is presented as a factual account of the Form 4 filing and recent corporate financing and analyst commentary included in public disclosures. It does not provide investment advice.